An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Trial Profile

An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Expanded access; Registrational
  • Acronyms CONSIGN
  • Sponsors Bayer
  • Most Recent Events

    • 11 Oct 2016 Subgroup analysis results presented at the 41st European Society for Medical Oncology Congress
    • 29 Jun 2016 Status changed from recruiting to completed.
    • 19 Jan 2016 Results of a subgroup analysis of patients in the USA will be presented at the 2016 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI), according to a Bayer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top